Guardant Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Audio By Carbonatix

PALO ALTO, Calif.--(BUSINESS WIRE)--Dec 29, 2025--

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the upcoming 44 th Annual J.P. Morgan Healthcare Conference in San Francisco.

Guardant Health’s management is scheduled to present and participate in a Q&A session on Monday, January 12, at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time. Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Source: Guardant Health, Inc.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251228899128/en/

CONTACT: Investor Contact:

Zarak Khurshid

investors@guardanthealth.comMedia Contact:

Meaghan Smith

press@guardanthealth.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH ONCOLOGY MEDICAL DEVICES

SOURCE: Guardant Health, Inc.

Copyright Business Wire 2025.

PUB: 12/29/2025 04:05 PM/DISC: 12/29/2025 04:05 PM

http://www.businesswire.com/news/home/20251228899128/en